Comparative Pharmacology
Head-to-head clinical analysis: AROMASIN versus LETROZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AROMASIN versus LETROZOLE.
AROMASIN vs LETROZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible steroidal aromatase inhibitor that binds to the aromatase enzyme, leading to its permanent inactivation via covalent modification. This reduces estrogen biosynthesis (primarily in peripheral tissues) by inhibiting conversion of androgens to estrogens.
Letrozole is a nonsteroidal aromatase inhibitor. It inhibits the aromatase enzyme, which converts androgens to estrogens, thereby reducing estrogen levels in postmenopausal women and suppressing estrogen-dependent tumor growth.
25 mg orally once daily after a meal
2.5 mg orally once daily
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) for exemestane, supporting once-daily dosing. Steady state achieved within 7 days.
Clinical Note
moderateLetrozole + Digoxin
"Letrozole may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateLetrozole + Digitoxin
"Letrozole may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateLetrozole + Deslanoside
"Letrozole may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateLetrozole + Acetyldigitoxin
"Letrozole may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life approximately 45 hours (range 42-52 hours). Steady-state achieved in 2-6 weeks with daily dosing.
Primarily hepatic metabolism via CYP3A4 and aldoketoreductases, with 60-70% of metabolites excreted renally and 30-40% via feces. Less than 1% excreted unchanged in urine.
Primarily hepatic metabolism (CYP3A4, CYP2A6) with 90% excreted in urine as metabolites (glucuronide conjugates) and 10% in feces. <6% excreted unchanged in urine.
Category C
Category D/X
Aromatase Inhibitor
Aromatase Inhibitor